



MATRIX Stakeholders Consultation Nairobi, Kenya

8-9 November 2022

DAY 1 – Tuesday, 8 November 2022

Time	Session	Title
08:15-09:00		Registration
09:00-09:45	Session 1	Welcome and Introductions <i>Wawira Nyagah, Dr. Nelly Mugo,</i> <i>Ministry of Health / National Syndemic Disease Control Council (NSDCC)</i>
CONTEXT AND SETTING THE STAGE		
09:45 -10:15	Session 2	Voices that Matter – and Why <ul style="list-style-type: none"> • Speaking to the HIV prevention needs of young women <i>Margaret Krigo, Jerop Limo</i> • A look at the current HIV prevention landscape <i>Daisy Ouya</i>
10:15-10:30	Session 3	MATRIX: Developing the next generation of HIV prevention products for women <i>Dr. Nelly Mugo</i>
10:30-10:45		Tea Break
10:45-11:15	Session 4	Understanding the Research & Development Process <i>Dr. Nelly Mugo</i> (15 mins) Questions and Discussion (15 mins) <i>Wawira Nyagah - Facilitator</i>
11:15-12:00	Session 5	Conducting early phase and first-in-human studies in sub-Saharan Africa <i>Prof. Kenneth Ngure</i> (15 mins) Experiences as a former Phase 1 trial participant <i>Steve Anguva</i> (5 mins) Questions and Discussion (20 mins) <i>Daisy Ouya - Facilitator</i>
SEEKING STAKEHOLDERS' VIEWS AND PERSPECTIVES (PART 1)		
12:00-13:00	Session 6	Is there a place for new methods and product formulations? <i>Nandi Luthuli - Facilitator</i>
13:00-14:00		Lunch
SEEKING STAKEHOLDERS' VIEWS AND PERSPECTIVES (PART 2)		
14:00 - 15:30	Session 7	TAF/EVG Fast-Dissolving Insert <ul style="list-style-type: none"> • What is the TAF/EVG Fast-Dissolving Insert? <i>Meredith Clark</i> (pre-recorded – 10 minutes) • MATRIX-001 Phase 1 Study of the TAF/EVG Fast-Dissolving Insert <i>Prof. Kenneth Ngure</i> (10 mins) • Open discussion and interactive session (75 mins) <i>Definate Nhamo - Facilitator</i>
15:30-15:45		Tea Break

(Day 1 Agenda continued)

SEEKING STAKEHOLDERS' VIEWS AND PERSPECTIVES (PART 3)		
15:45-17:00	Session 8	<p>One-Month Dapivirine Vaginal Film</p> <ul style="list-style-type: none"> • What is the one-month dapivirine vaginal film? <i>Lisa Rohan</i> (pre-recorded – 5 minutes) • MATRIX-002 Acceptability and Safety Study of Two Prototype Vaginal Films <i>Dr. Nelly Mugo</i> (10 mins) • Open discussion and interactive session (60 mins) Nandi Luthuli - <i>Facilitator</i>
17:00-17:05		<p>Closing Remarks for Day One <i>Dr. Nelly Mugo</i></p>
18:30- 21:00		Reception and Dinner

DAY 2 – Wednesday, 9 November 2022

Time	Session	Title
09:00-09:30	Session 1	<p>Day One Recap and Outstanding Questions <i>Dr. Nelly Mugo</i> Wawira Nyagah - <i>Facilitator</i></p>
SEEKING STAKEHOLDERS' VIEWS AND PERSPECTIVES (PART 4)		
09:30-10:30	Session 2	<p>Non-Antiretroviral (ARV)/Nonhormonal Contraceptive Multipurpose Vaginal Ring (Also called the LAMP-IVR)</p> <ul style="list-style-type: none"> • What is the non-ARV/nonhormonal contraceptive multipurpose vaginal ring? <i>Marc Baum</i> (pre-recorded – 10 minutes) • Open discussion and interactive session (50 mins) Definate Nhamo - <i>Facilitator</i>
10:30-10:45		Tea Break
10:45-11:00	Session 3	<p>Looking farther ahead</p> <ul style="list-style-type: none"> • What is the Griffithsin Fast-Dissolving Insert? <i>Lisa Haddad</i> (pre-recorded – 5 minutes) • What are the Cabotegravir Dissolvable Pellet Implants and the Cabotegravir Injectable Depot? <i>Gustavo Doncel</i> (pre-recorded – 10 minutes) Imelda Mahaka - <i>Facilitator</i>
SEEKING STAKEHOLDERS' VIEWS AND PERSPECTIVES (PART 5)		
11:00-11:30	Session 4	<p>A few final questions Nandi Luthuli- <i>Facilitator</i></p>
11:30-12:00	Session 5	<p>What do young women think? What do others think? Jacque Wambui - <i>Facilitator</i></p>
12-12:45	Session 6	<p>Meeting Evaluation Summary and Next Steps <i>Prof. Kenneth Ngure, Wawira Nyagah</i></p>
13:00-14:00		Lunch